Ruth Lopert

Experience

• –present
  Adjunct Professor of Health Policy, George Washington University

Education

•  
  ANU, BSc
• 2001 
  University of Newcastle, MMedSc
• 1996 
  University of Newcastle, BMed

Publications

• 2015
  Pharma’s next frontier? New Threats to Public Health in the Regional Comprehensive Economic Partnership Agreement. , Aust NZ J Public Health
• 2015
  Value-Based Purchasing and Disinvestment Strategies for Pharmaceuticals: An International Review. , Pharmacoeconomics
• 2015
  Impact d’un “Qualifiant Biologique“ sur le droit de la Dénomination Commune Internationale des biomolecules., Rev Gen Dr Med
• 2015
  Costs to Australian taxpayers of pharmaceutical monopolies and proposals to extend them in the Trans Pacific Partnership Agreement. , Med J Aust
• 2014
  Transferability of results of cost utility analyses for biologicals for inflammatory conditions in Central and Eastern European countries. , Eur J Health Econ
• 2014
  Faecal microbiota transplantation: A sui generis biological drug, not a tissue. , Ann Pharm France
• 2014
  Substitution des biomédicaments: Prospective d’impact compétitif en droit comparé franco-américain. , Techniques Hospitalières
• 2014
  Costs of New Treatments for Hepatitis C Infection , JAMA
• 2014
  Revolution then evolution: The advance of health economic evaluation in Australia., Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen
• 2013
  Australia’s ‘Fourth Hurdle’ drug review comparing costs and benefits holds lessons for the United States., Health Affairs
• 2013
  Applying rapid ‘de facto’ HTA in resource-limited settings: Experience from Romania., Health Policy
• 2013
  Likely impact of the Trans Pacific Partnership Agreement on access to affordable medicines and health equity in New Zealand. , Health Policy
• 2013
  Biosimilars and the European Experience: Implications for the United States. , Health Affairs
• 2013
  Increased risk of intussusception associated with rotavirus vaccines in Australia’s national immunization program. , Clin Inf Dis
• 2013
  The high price of “free” trade: US free trade agreements and access to medicines., J Law Med Ethics
• 2012
  Persistence in health behaviors among Medicare beneficiaries. , Open Journal of Preventive Medicine
• 2012
  Impact of Medication Adherence on Medicare Expenditure among Beneficiaries with Heart Failure, Am J Man Care
• 2012
  Willingness to Pay for Cancer Therapy. , Health Affairs
• 2012
  Medication information for patients with limited English proficiency: Lessons from the European Union. , J Law Med Ethics
• 2012
  Simulated Value-Based Insurance Design Applied to Statin Use by Medicare Beneficiaries with Diabetes, Value in Health
• 2011
  . Does Medication Adherence Lower Medicare Spending among Medicare Beneficiaries with Diabetes? , Health Services Research
• 2010
  Child influenza vaccination: Panvax febrile reactions not a predictor. , BMJ
• 2010
  Benefits and risks of trivalent 2010 seasonal influenza vaccine in Australian children, Eurosurveillance
• 2009
  Comparative Effectiveness Research and Evidence- Based Health Policy: Experience from Four Countries. , Milbank Quarterly
• 2009
  PBS Co-payments and Safety Nets. , Aust Health Review
• 2009
  Medicines and Markets: the USA and Australia. , Australian Prescriber
• 2008
  Toward a Definition of Pharmaceutical Innovation. , Open Medicine
• 2007
  Prices for innovative pharmaceutical products that provide health gain: a comparison between Australia and USA. , Value in Health
• 2007
  What is fair? Choice, Fairness, and Transparency in Access to Prescription Medicines in the US and Australia. , J Law Med Ethics
• 2007
  Towards a rational, value-based drug benefit for Medicare. , Health Affairs
• 2007
  International Price Comparisons for Novel and Follow-on Drugs: A Response. , Value in Health
• 2003
  Use of pharmacoeconomics in prescribing research. Part 3: Cost- effectiveness analysis. , J Clin Pharm Ther
• 2003
  Use of pharmacoeconomics in prescribing research. Part 5: Modeling – beyond clinical trials. , J Clin Pharm Ther
• 2002
  The Pharmaceutical Benefits Scheme: Economic evaluation works ... but is not a panacea. , Australian Prescriber
• 2002
  Differential pricing of drugs: A role for cost effectiveness analysis? , Lancet
• 1999
  Pharmacoeconomics and policy decisions: The Australian health care system., Clin Ther
• 1997
  A randomised controlled trial of piroxicam in the management of acute ankle sprain in Australian Regular Army recruits., Am J Sports Med
• 1996
  Drug-induced delirium: Incidence, management and prevention. , Drug Safety

Professional Memberships

• Fellow of the Faculty of Public Health Medicine, Royal Australasian College of Physicians

Honours

20006-07 Harkness Fellow in Health Policy